Analysis of Prognostic Factors in Surgical Resection After mFOLFOX6 Plus Bevacizumab or mFOLFOX6 Plus Panitumumab in Chemotherapy-Naive Patients with Unresectable Advanced or Recurrent Colorectal Cancer with Wild-Type RAS (KRAS/NRAS) Genes

Analysis of Prognostic Factors in Surgical Resection After mFOLFOX6 Plus Bevacizumab or mFOLFOX6 Plus Panitumumab in Chemotherapy-Naive Patients with Unresectable Advanced or Recurrent Colorectal Cancer with Wild-Type RAS (KRAS/NRAS) Genes - Analysis of Prognostic Factors in Surgical Resection After mFOLFOX6 Plus Bevacizumab or mFOLFOX6 Plus Panitumumab in Chemotherapy-Naive Patients with Unresectable Advanced or Recurrent Colorectal Cancer with Wild-Type RAS (KRAS/NRAS) Genes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058419

Enrollment

156

Registered

2025-07-10

Start date

2025-07-14

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with chemotherapy-naive RAS, wild-type, unresectable metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who were enrolled in the PARADIGM trial at 197 domestic institutions between March 2015 and July 2017 and underwent conversion surgery after receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus panitumumab (excluding cases that were not included in the efficacy analysis of the PARADIGM trial).

Exclusion criteria

Exclusion criteria: 1. Patients deemed inappropriate for participation in this study by the principal investigator or researchers. 2. Patients who have expressed their wish not to participate in the study.

Design outcomes

Primary

Measure	Time frame
Overall survival (OS),progression-free survival (PFS),and recurrence-free survival (RFS) in the conversion surgery cohort OS,PFS,and RFS in the conversion surgery cohort,stratified by liver-limited vs.non-liver-limited metastases OS,PFS,and RFS in the conversion surgery cohort,stratified by tumor-associated gene mutations OS and PFS in the entire study population OS and PFS in the entire study population,stratified by liver-limited vs.non-liver-limited metastases OS and PFS in the entire study population,stratified by tumor-associated gene mutations	—

Measure

Time frame

Overall survival (OS),progression-free survival (PFS),and recurrence-free survival (RFS) in the conversion surgery cohort OS,PFS,and RFS in the conversion surgery cohort,stratified by liver-limited vs.non-liver-limited metastases OS,PFS,and RFS in the conversion surgery cohort,stratified by tumor-associated gene mutations OS and PFS in the entire study population OS and PFS in the entire study population,stratified by liver-limited vs.non-liver-limited metastases OS and PFS in the entire study population,stratified by tumor-associated gene mutations

—

Countries

Japan

Contacts

Public ContactTetsuro Kawazoe

Graduate School of Medical Sciences, Kyushu University Department of Surgery and Science

kawazoe.tetsuro.857@m.kyushu-u.ac.jp092-642-5466

Outcome results